Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424018 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
A Phase 3 study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Active
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
- 20
- Study locations
NCT03424018 is a Phase 3 study of Achondroplasia that is active but no longer recruiting, run by BioMarin Pharmaceutical. The registered enrollment target is 119 participants, below the 138-participant average among 9 other Achondroplasia trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT03424018, a Phase 3 study of Achondroplasia, is active but no longer recruiting, sponsored by BioMarin Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Conditions Studied
Interventions
- DRUG BMN 111
Study Locations (20)
Other
- Otto-von-Gericke Universitaet, Universitaetskinderklinik - Magdeburg
- Universitätsklinikum Münster - Münster
- Osaka University Hospital - Osaka
- Saitama Children's Medical Center - Saitama
- Tokushima University Hospital - Tokushima
- Institut Catala de Traumatologica I Medicina de l'Esport - Barcelona
- Hospital Sant Joan de Deu - Barcelona
California
- Children's Hospital & Research Center Oakland - Oakland
- Harbor - UCLA Medical Center - Torrance
Delaware
- Alfred I. duPont Hospital for Children - Wilmington
Georgia
- Emory University - Atlanta
Illinois
- Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
Missouri
- University of Missouri - Columbia
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2031-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03424018
The ClinicalTrials.gov registry entry for NCT03424018 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 9 other Achondroplasia trials with a reported enrollment target (14% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 1 intervention - of which BMN 111 is the first listed.
NCT03424018 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT03424018 about?
NCT03424018 is a clinical study titled "An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia". The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
What is the current status of trial NCT03424018?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2017-12-12. Estimated completion is 2031-06.
What conditions does trial NCT03424018 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT03424018?
The interventions under investigation include: BMN 111 (DRUG).
Who is sponsoring clinical trial NCT03424018?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03424018 being conducted?
This trial has 20 study locations across California, Delaware, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.